AI brief of an SEC Form 8-K · NEXGEL, INC. (NXGL)

NexGel Ends CEO Adam Levy's Employment; Director Brian Kieser Named Interim CEO

Negative Impact 4 of 5 leadership Written later

NexGel terminated CEO Adam R. Levy without Cause effective August 21, 2026, and Levy resigned from the Board. The Board appointed director Brian Kieser as Interim CEO, and formed a Special Committee to review strategic alternatives, liquidity and non-core assets.

Key points

Levy's employment was terminated without Cause effective August 21, 2026; he also resigned from the Board and all other company positions.
Brian Kieser, a Board member since May 6, 2026, is Interim CEO. He is also CEO of Sequence LifeScience, which has a strategic partnership with NexGel.
The Special Committee, chaired by Kevin Harris with Steve Glassman, expects to present a strategic and value creation framework to the Board within 30 to 45 days.
The separation agreement with Levy and Kieser's compensation terms have not been finalized; the company will file an 8-K amendment once they are.

The filing

CompanyNEXGEL, INC. (NXGL)

Form8-K, current report

Filed with the SECAug 21, 2026, 4:42 PM ET

Accession number0001493152-26-039708

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.